These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 32089398)
21. Mesenchymal stem cells administered after liver transplantation prevent acute graft-versus-host disease in rats. Xia X; Chen W; Ma T; Xu G; Liu H; Liang C; Bai X; Zhang Y; He Y; Liang T Liver Transpl; 2012 Jun; 18(6):696-706. PubMed ID: 22344929 [TBL] [Abstract][Full Text] [Related]
22. Adoptive Transfer of Treg Cells Combined with Mesenchymal Stem Cells Facilitates Repopulation of Endogenous Treg Cells in a Murine Acute GVHD Model. Lee ES; Lim JY; Im KI; Kim N; Nam YS; Jeon YW; Cho SG PLoS One; 2015; 10(9):e0138846. PubMed ID: 26393514 [TBL] [Abstract][Full Text] [Related]
23. Intestinal helminths regulate lethal acute graft-versus-host disease and preserve the graft-versus-tumor effect in mice. Li Y; Chen HL; Bannick N; Henry M; Holm AN; Metwali A; Urban JF; Rothman PB; Weiner GJ; Blazar BR; Elliott DE; Ince MN J Immunol; 2015 Feb; 194(3):1011-20. PubMed ID: 25527786 [TBL] [Abstract][Full Text] [Related]
26. Mesenchymal Stromal Cell (MSC)-Derived Combination of CXCL5 and Anti-CCL24 Is Synergistic and Superior to MSC and Cyclosporine for the Treatment of Graft-versus-Host Disease. Fan X; Guo D; Cheung AMS; Poon ZY; Yap CS; Goh SE; Guo D; Li H; Bari S; Li S; Lim KH; Hwang WYK Biol Blood Marrow Transplant; 2018 Oct; 24(10):1971-1980. PubMed ID: 29883796 [TBL] [Abstract][Full Text] [Related]
27. Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4+CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model. Yang J; Fan H; Hao J; Ren Y; Chen L; Li G; Xie R; Yang Y; Qian K; Liu M Transfusion; 2012 Jun; 52(6):1333-47. PubMed ID: 22098312 [TBL] [Abstract][Full Text] [Related]
28. Enhancement of Graft-Versus-Host Disease Control Efficacy by Adoptive Transfer of Type 1 Regulatory T Cells in Bone Marrow Transplant Model. Jeon YW; Lim JY; Im KI; Kim N; Nam YS; Song YJ; Cho SG Stem Cells Dev; 2019 Jan; 28(2):129-140. PubMed ID: 30381994 [TBL] [Abstract][Full Text] [Related]
29. Mesenchymal stem cells targeting the GVHD. Wang L; Zhao RC Sci China C Life Sci; 2009 Jul; 52(7):603-9. PubMed ID: 19641864 [TBL] [Abstract][Full Text] [Related]
30. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation. Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866 [TBL] [Abstract][Full Text] [Related]
31. The role of regulatory T cells in graft-versus-host disease management. Whangbo JS; Antin JH; Koreth J Expert Rev Hematol; 2020 Feb; 13(2):141-154. PubMed ID: 31874061 [No Abstract] [Full Text] [Related]
32. Remestemcel-L, the first cellular therapy product for the treatment of graft-versus-host disease. Daly A Drugs Today (Barc); 2012 Dec; 48(12):773-83. PubMed ID: 23243634 [TBL] [Abstract][Full Text] [Related]
33. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
35. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation. Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510 [TBL] [Abstract][Full Text] [Related]
36. [Mesenchymal stem cells for treatment of graft-versus-host disease]. Najima Y Rinsho Ketsueki; 2017; 58(12):2440-2449. PubMed ID: 29332881 [TBL] [Abstract][Full Text] [Related]
37. Third-party regulatory T cells prevent murine acute graft-versus-host disease. Lim JY; Im KI; Song Y; Kim N; Nam YS; Jeon YW; Cho SG Korean J Intern Med; 2018 Sep; 33(5):980-989. PubMed ID: 29050459 [TBL] [Abstract][Full Text] [Related]
38. Experimental therapy of graft-versus-host disease by mesenchymal stromal cells grown on oxide nanocoatings. Goltsev AN; Rassokha IV; Dubrava TG; Ostankova LV; Ostankov MV; Safonov VI; Zykova AV Fiziol Zh (1994); 2016; 62(5):3-11. PubMed ID: 30204336 [TBL] [Abstract][Full Text] [Related]
39. Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects. Wang L; Ni M; Hückelhoven-Krauss A; Sellner L; Hoffmann JM; Neuber B; Luft T; Hegenbart U; Schönland S; Kleist C; Sill M; Chen BA; Wuchter P; Eckstein V; Krüger W; Hilgendorf I; Yerushalmi R; Nagler A; Müller-Tidow C; Ho AD; Dreger P; Schmitt M; Schmitt A Front Immunol; 2018; 9():2207. PubMed ID: 30349527 [TBL] [Abstract][Full Text] [Related]
40. Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis. Morata-Tarifa C; Macías-Sánchez MDM; Gutiérrez-Pizarraya A; Sanchez-Pernaute R Stem Cell Res Ther; 2020 Feb; 11(1):64. PubMed ID: 32070420 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]